Management also emphasized refill behavior. Maraoui said the third quarter of 2025 saw approximately one refill for every new prescription, and by the end of 2025 the ratio had risen to 1.4 refills per new prescription. He said the company expects that ratio to continue to grow, citing rosacea’s chronic nature and relapse patterns.Journey ended 2025 with about 3,200 unique EMROSI prescribers, meeting its initial goal focused on high-volume writers of ORACEA and similar products. The company later updated th ...